BRPI1007737A2 - "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii" - Google Patents

"composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"

Info

Publication number: BRPI1007737A2
Authority: BR; Brazil
Prior art keywords: compound; formula; preparing; median; disorder
Prior art date: 2009-04-20

Application number

BRPI1007737-5A

Other languages

English (en)

Inventor

Tadimeti S Rao

Chengzhi Zhang

Original Assignee

Auspex Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-20

Filing date

2010-04-20

Publication date

2015-09-01

2010-04-20 Application filed by Auspex Pharmaceuticals Llc filed Critical Auspex Pharmaceuticals Llc

2015-09-01 Publication of BRPI1007737A2 publication Critical patent/BRPI1007737A2/pt

Links

150000001875 compounds Chemical class 0.000 title 2
102000006500 Janus Kinase 3 Human genes 0.000 title 1
108010019421 Janus Kinase 3 Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

BRPI1007737-5A 2009-04-20 2010-04-20 "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii" BRPI1007737A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17085809P	2009-04-20	2009-04-20
US30088710P	2010-02-03	2010-02-03
PCT/US2010/031773 WO2010123919A2 (en)	2009-04-20	2010-04-20	Piperidine inhibitors of janus kinase 3

Publications (1)

Publication Number	Publication Date
BRPI1007737A2 true BRPI1007737A2 (pt)	2015-09-01

Family

ID=43011721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007737-5A BRPI1007737A2 (pt)	2009-04-20	2010-04-20	"composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"

Country Status (10)

Country	Link
US (4)	US8299084B2 (pt)
EP (2)	EP2421867B1 (pt)
JP (3)	JP5709276B2 (pt)
KR (1)	KR20130009577A (pt)
CN (2)	CN104817561B (pt)
AU (2)	AU2010239396B2 (pt)
BR (1)	BRPI1007737A2 (pt)
CA (2)	CA3025627C (pt)
ES (1)	ES2552805T3 (pt)
WO (1)	WO2010123919A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3025627C (en)	2009-04-20	2021-08-31	Auspex Pharmaceuticals, Inc.	Piperidine inhibitors of janus kinase 3
EP2481411A1 (en) *	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
US20120195966A1 (en) *	2011-01-27	2012-08-02	Frank Sievert	Oral dosage form for modified release comprising a jak3 inhibitor
EP2675275B1 (en)	2011-02-14	2017-12-20	The Regents Of The University Of Michigan	Compositions and methods for the treatment of obesity and related disorders
WO2014028595A1 (en) *	2012-08-14	2014-02-20	Concert Pharmaceuticals, Inc.	Deuterated ponatinib
CN102875555A (zh) *	2012-09-27	2013-01-16	同济大学	一种JAK抑制剂Tofacitinib的合成方法
US9481679B2 (en) *	2012-12-17	2016-11-01	Sun Pharmaceutical Industries Limited	Process for the preparation of tofacitinib and intermediates thereof
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9670160B2 (en)	2012-12-28	2017-06-06	Glenmark Pharmaceuticals Limited	Process for the preparation of tofacitinib and intermediates thereof
MX2015008829A (es)	2013-01-09	2016-04-25	Concert Pharmaceuticals Inc	Momelotinib deuterado.
PE20191245A1 (es)	2013-01-15	2019-09-18	Incyte Holdings Corp	Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN103965114B (zh) *	2013-01-28	2016-01-06	苏州泽璟生物制药有限公司	氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
CN103073552B (zh) *	2013-02-05	2015-08-12	华润赛科药业有限责任公司	一种无定型枸橼酸托法替尼的制备方法
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
CA2910766C (en)	2013-04-30	2020-12-15	Otitopic Inc.	Dry powder formulations and methods of use
US8946424B2 (en)	2013-05-02	2015-02-03	The Regents Of The University Of Michigan	Deuterated amlexanox
WO2014195978A2 (en) *	2013-06-05	2014-12-11	Msn Laboratories Limited	PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CN104447752A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼水合物及其制备方法
CN104447751A (zh) *	2013-09-16	2015-03-25	天津市汉康医药生物技术有限公司	一种托法替尼化合物
CN104292231B (zh) *	2013-09-17	2016-11-30	广东东阳光药业有限公司	一种枸橼酸托法替尼的制备方法
CN104513248B (zh) *	2013-09-30	2019-05-24	重庆医药工业研究院有限责任公司	一种托法替尼中间体的纯化方法
WO2015051738A1 (en) *	2013-10-08	2015-04-16	Sunshine Lake Pharma Co., Ltd.	Tofacitinib citrate
CN103819474A (zh) *	2013-11-04	2014-05-28	湖南华腾制药有限公司	一种托法替尼的制备方法
US9951012B2 (en)	2013-12-09	2018-04-24	Unichem Laboratories Limited	Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
WO2015120110A2 (en)	2014-02-07	2015-08-13	Auspex Pharmaceuticals, Inc.	Novel pharmaceutical formulations
US20150284327A1 (en) *	2014-04-04	2015-10-08	Auspex Pharmaceuticals, Inc.	Oxindole inhibitors of tyrosine kinase
CN104710346B (zh) *	2015-02-15	2017-04-12	江苏苏利精细化工股份有限公司	一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法
EP3078665A1 (en)	2015-04-10	2016-10-12	OLON S.p.A.	Efficient method for the preparation of tofacitinib citrate
UA118822C2 (uk) *	2015-05-29	2019-03-11	Вуксі Фортуне Фармасьютікал Ко., Лтд	Інгібітор янус-кінази
AR105967A1 (es) *	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
WO2017059251A1 (en)	2015-10-02	2017-04-06	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
CN105440039A (zh) *	2015-11-24	2016-03-30	山东淄博新达制药有限公司	枸橼酸托法替布的合成方法
EP3407974A4 (en)	2016-01-29	2019-08-28	The Regents Of The University Of Michigan	Amlexanox Analogs
CN105884781B (zh) *	2016-04-18	2018-04-20	山东罗欣药业集团股份有限公司	一种枸橼酸托法替布的制备方法
CN106188064A (zh) *	2016-07-07	2016-12-07	国药集团容生制药有限公司	一种N‑甲基‑N‑((3R，4R)‑4‑甲基吡啶‑3‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑4‑胺的制备方法
CN105949204A (zh) *	2016-07-25	2016-09-21	国药集团容生制药有限公司	一种N-((3R，4R)-1-苄基-4-甲基吡啶-3-基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺的制备方法
EP3421455B1 (en) *	2017-06-29	2019-03-27	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib
CN109293682A (zh) *	2017-07-25	2019-02-01	重庆医药工业研究院有限责任公司	一种托法替布杂质及其制备方法
US10786456B2 (en)	2017-09-22	2020-09-29	Otitopic Inc.	Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en)	2017-09-22	2019-03-28	Otitopic Inc.	Dry powder compositions with magnesium stearate
CN108358930A (zh) *	2018-02-05	2018-08-03	南京法恩化学有限公司	一种枸橼酸托法替尼的制备方法
CN109776547A (zh) *	2019-03-22	2019-05-21	北京新领先医药科技发展有限公司	一种枸橼酸托法替布的制备方法
JP7747664B2 (ja) *	2020-05-20	2025-10-01	エフ．ホフマン－ラロシュアーゲー	質量分析のためのベンジルピリジニウム試薬
CN111848496B (zh) *	2020-07-28	2021-10-08	湖南华纳大药厂手性药物有限公司	一种托法替布中间体胺及其双盐酸盐的制备方法
CN112679508B (zh) *	2021-03-09	2021-08-10	正大天晴药业集团南京顺欣制药有限公司	一种托法替布中间体的制备方法
WO2023248010A2 (en)	2022-06-23	2023-12-28	Synovo Gmbh	Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
US20250102479A1 (en) *	2023-09-22	2025-03-27	Thermo Finnigan Llc	Method of utilizing deuterium gas for chromatography applications, deuterium gas generator and devices for conservation thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221335B1 (en)	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
ES2293638T3 (es)	1994-03-25	2008-03-16	Isotechnika, Inc.	Mejora de la eficacia de farmacos por deuteracion.
PT783490E (pt) *	1994-09-30	2002-06-28	Novartis Erfind Verwalt Gmbh	Compostos de 1-acil-4-alifatilaminopiperidina
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
TW505646B (en)	1998-06-19	2002-10-11	Pfizer Prod Inc	Pyrrolo [2,3-d] pyrimidine compounds
US6440710B1 (en)	1998-12-10	2002-08-27	The Scripps Research Institute	Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en)	1999-12-03	2003-03-12	Pfizer Products Inc.	Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
PT1382339E (pt)	1999-12-10	2008-02-06	Pfizer Prod Inc	Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
EP1134290A3 (en)	2000-03-14	2004-01-02	Pfizer Products Inc.	Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
PL359563A1 (pl)	2000-06-26	2004-08-23	Pfizer Products Inc.	Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
PY0228255A (es) *	2001-12-06	2004-06-01	Pfizer Prod Inc	Compuestos cristalinos novedosos
TW200413273A (en)	2002-11-15	2004-08-01	Wako Pure Chem Ind Ltd	Heavy hydrogenation method of heterocyclic rings
KR100678800B1 (ko)	2002-11-21	2007-02-05	화이자 프로덕츠 인코포레이티드	3-아미노-피페리딘 유도체 및 그의 제조 방법
WO2004047843A1 (en)	2002-11-26	2004-06-10	Pfizer Products Inc.	Method of treatment of transplant rejection
CA2545192A1 (en) *	2003-11-25	2005-06-09	Pfizer Products Inc.	Method of treatment of atherosclerosis
US20050137684A1 (en)	2003-12-17	2005-06-23	Pfizer Inc	Stent with therapeutically active drug coated thereon
WO2005063251A1 (en)	2003-12-17	2005-07-14	Pfizer Products Inc.	Modified stent useful for delivery of drugs along stent strut
CA2549485A1 (en)	2003-12-17	2005-07-07	Pfizer Products Inc.	Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
WO2005063318A1 (en)	2003-12-17	2005-07-14	Pfizer Products Inc.	Stent with therapeutically active drug coated thereon
KR20070006889A (ko)	2004-05-03	2007-01-11	노파르티스 아게	Ｓ1ｐ 수용체 작용제 및 ｊａｋ3 키나제 억제제를 포함하는조합물
WO2006013114A1 (en)	2004-08-06	2006-02-09	Develogen Aktiengesellschaft	Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
BRPI0517887A (pt)	2004-11-24	2008-10-21	Novartis Ag	combinações de inibidores de jaks
EP1879591B8 (en)	2005-05-04	2012-04-04	DeveloGen Aktiengesellschaft	Use of azapaullones for preventing and treating pancreatic autoimmune disorders
EP1885454A2 (en)	2005-05-04	2008-02-13	DeveloGen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
WO2006136374A2 (en)	2005-06-20	2006-12-28	Develogen Aktiengesellschaft	Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
US20080033011A1 (en)	2005-07-29	2008-02-07	Concert Pharmaceuticals Inc.	Novel benzo[d][1,3]-dioxol derivatives
CA2614907C (en)	2005-07-29	2012-02-28	Pfizer Products Inc.	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
US7750168B2 (en)	2006-02-10	2010-07-06	Sigma-Aldrich Co.	Stabilized deuteroborane-tetrahydrofuran complex
GB0605691D0 (en)	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
WO2008029237A2 (en) *	2006-09-05	2008-03-13	Pfizer Products Inc.	Combination therapies for rheumatoid arthritis
MX2009010946A (es)	2007-04-11	2009-10-29	Alcon Res Ltd	Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
US20090182035A1 (en)	2007-04-11	2009-07-16	Alcon Research, Ltd.	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2009007839A1 (en)	2007-07-11	2009-01-15	Pfizer Inc.	Pharmaceutical compositions and methods of treating dry eye disorders
EA019507B1 (ru)	2008-05-13	2014-04-30	Айрм Ллк	Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
HUE028347T2 (en)	2008-06-10	2016-12-28	Abbvie Inc	Tricyclic compounds
CA3025627C (en)	2009-04-20	2021-08-31	Auspex Pharmaceuticals, Inc.	Piperidine inhibitors of janus kinase 3

2010
- 2010-04-20 CA CA3025627A patent/CA3025627C/en active Active
- 2010-04-20 US US12/763,858 patent/US8299084B2/en active Active
- 2010-04-20 WO PCT/US2010/031773 patent/WO2010123919A2/en not_active Ceased
- 2010-04-20 ES ES10767652.0T patent/ES2552805T3/es active Active
- 2010-04-20 CA CA2759026A patent/CA2759026C/en active Active
- 2010-04-20 JP JP2012506006A patent/JP5709276B2/ja active Active
- 2010-04-20 AU AU2010239396A patent/AU2010239396B2/en active Active
- 2010-04-20 EP EP10767652.0A patent/EP2421867B1/en active Active
- 2010-04-20 BR BRPI1007737-5A patent/BRPI1007737A2/pt not_active IP Right Cessation
- 2010-04-20 EP EP15002523.7A patent/EP3026052A1/en not_active Withdrawn
- 2010-04-20 CN CN201510171918.7A patent/CN104817561B/zh active Active
- 2010-04-20 KR KR1020117026990A patent/KR20130009577A/ko not_active Ceased
- 2010-04-20 CN CN201080025178.1A patent/CN102459270B/zh active Active
2012
- 2012-09-26 US US13/627,747 patent/US8962638B2/en active Active
2015
- 2015-01-14 US US14/596,784 patent/US9493469B2/en active Active
- 2015-02-26 JP JP2015037398A patent/JP5932080B2/ja active Active
2016
- 2016-04-20 JP JP2016084849A patent/JP6145534B2/ja active Active
- 2016-07-18 AU AU2016206214A patent/AU2016206214B2/en active Active
- 2016-08-05 US US15/229,267 patent/US9856261B2/en active Active

Also Published As

Publication number	Publication date
WO2010123919A3 (en)	2011-03-03
AU2016206214A1 (en)	2016-08-11
EP2421867A2 (en)	2012-02-29
US20130040974A1 (en)	2013-02-14
US20150322070A1 (en)	2015-11-12
CA2759026C (en)	2019-01-15
US20100291026A1 (en)	2010-11-18
JP5709276B2 (ja)	2015-04-30
JP6145534B2 (ja)	2017-06-14
JP2015129164A (ja)	2015-07-16
AU2016206214B2 (en)	2017-11-23
JP5932080B2 (ja)	2016-06-08
CN104817561B (zh)	2017-06-13
US20160340361A1 (en)	2016-11-24
ES2552805T3 (es)	2015-12-02
US9493469B2 (en)	2016-11-15
CA3025627A1 (en)	2010-10-28
US8299084B2 (en)	2012-10-30
CN102459270A (zh)	2012-05-16
CN102459270B (zh)	2015-04-29
US8962638B2 (en)	2015-02-24
KR20130009577A (ko)	2013-01-23
CN104817561A (zh)	2015-08-05
AU2010239396A1 (en)	2011-11-03
EP3026052A1 (en)	2016-06-01
JP2012524085A (ja)	2012-10-11
JP2016175919A (ja)	2016-10-06
CA2759026A1 (en)	2010-10-28
EP2421867A4 (en)	2012-10-10
WO2010123919A2 (en)	2010-10-28
EP2421867B1 (en)	2015-09-02
AU2010239396B2 (en)	2016-06-23
EP3026052A9 (en)	2016-12-07
US9856261B2 (en)	2018-01-02
CA3025627C (en)	2021-08-31

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A E 5A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI1007737A2 (pt)	2015-09-01	"composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
MX2013007336A (es)	2013-08-01	Compuestos de bi-heteroarilo como inhibidores de vps34.
BRPI0909614A2 (pt)	2015-09-22	"composto, composição farmacêutica, método de tratamento de um transtorno hiperproliferativo em um mamífero, processo para a preparação de uma composição farmacêutica, método para a inibição ou modulação da atividade de quinase de lipídio em um mamífero, kit para o tratamento de condição mediada por pi3k e método de preparação de um composto da fórmula
WO2010108074A3 (en)	2010-11-18	Inhibitors of pi3 kinase
BRPI1009637A2 (pt)	2019-04-30	composto, composição e uso de um composto
WO2013040286A3 (en)	2013-05-10	Pharmaceutical compositions
EP2300013A4 (en)	2012-09-12	Phosphorus derivatives as kinase inhibitors
BR112012012903A2 (pt)	2017-03-01	compostos de espiropiperidina
EA201100503A1 (ru)	2011-10-31	Глюкозидные производные и их применения
CR20110195A (es)	2011-06-08	Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
UA106037C2 (uk)	2014-07-25	Модулятори ampk (амф-активованої протеїнкінази)
PL2724720T3 (pl)	2018-09-28	Kompozycje fenylefryny użyteczne do leczenia choroby dróg oddechowych
MX2012004420A (es)	2012-05-08	Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
PL2785711T3 (pl)	2017-01-31	Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
WO2007138282A3 (en)	2008-02-28	Bi-aryl or aryl-heteroaryl substituted indoles
TW201144306A (en)	2011-12-16	Bicyclic heteroaryl analogues as GPR119 modulators
EP2157864A4 (en)	2013-09-11	STABILIZED PICOPLATIN DOSAGE FORM
BRPI1014802B8 (pt)	2021-05-25	profármacos de triptolida.
BR112012020585A2 (pt)	2018-04-17	composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
UA103500C2 (uk)	2013-10-25	Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
EP2599814A4 (en)	2016-09-07	COMPOUND, RADIATION SENSITIVE COMPOSITION, AND METHOD FOR FORMING A RESISTANCE STRUCTURE
WO2010150211A3 (en)	2011-08-25	Use of derivatives of indoles for the treatment of cancer
IL199891A (en)	2016-05-31	Aqueous preparations of (e) - 2, 4, 6 - trimethoxystyril - 3 - carboxymethylamino - 4 - methoxybenzylsulfone for intravenous administration
BRPI0905687A2 (pt)	2015-07-07	"composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"